Paper Details

  1. Home
  2. Paper Details

Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD.

Author: CorteseSamuele, NageyeFatuma

Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review explores recent randomized controlled trials on novel non-stimulant medications for attention-deficit/hyperactivity disorder (ADHD), including Dasotraline, Viloxazine, Centanafadine SR, OPC-64005, Fasoracetam, Metadoxine, Vortioxetine, Tipepidine Hibenzate, Oxytocin, Sativex, Mazindol, and Molindone hydrochloride. While these agents may not surpass stimulants in efficacy, they might offer comparable or better tolerability and contribute to a more personalized approach to ADHD treatment.
Paper Details　
Original Abstract of the Article :
<b>Introduction</b>: Despite stimulants being highly efficacious in short-term randomized controlled trials (RCTs), not all patients respond or can successfully tolerate them. A number of novel non-stimulant options are currently in the pipeline for the treatment of attention-deficit/hyperactivity ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14737175.2019.1628640

データ提供：米国国立医学図書館（NLM）

Beyond Stimulants: New Frontiers in ADHD Treatment

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent condition that often requires medication to manage symptoms. This systematic review explores the growing field of non-stimulant treatments for ADHD, examining randomized controlled trials (RCTs) of novel compounds targeting various biological pathways. The authors found numerous promising candidates, including Dasotraline, Viloxazine, Centanafadine, OPC-64005, Fasoracetam, Metadoxine, Vortioxetine, Tipepidine Hibenzate, Oxytocin, Sativex, Mazindol, and Molindone. While these agents may not surpass stimulants in terms of overall efficacy, they offer potential advantages in tolerability and may prove particularly beneficial for specific subgroups of patients.

Expanding the Oasis: New Treatment Options for ADHD

This review offers a glimpse into the expanding landscape of ADHD treatment options. It's like discovering new springs in a vast desert, providing hope for those seeking relief from ADHD symptoms. These promising new compounds represent a significant step forward in personalized medicine, allowing for a more tailored approach to managing this complex condition.

Navigating the Desert of ADHD: Finding the Right Path

This research highlights the importance of finding the right treatment for each individual with ADHD. It's like navigating a vast desert, where different paths lead to different destinations. Some individuals may respond best to stimulants, while others may find relief with non-stimulant options. This study encourages continued exploration and development of new treatments, allowing us to find the most effective and personalized approaches for all patients.

Dr. Camel's Conclusion

This systematic review brings us closer to the goal of providing more individualized treatment for ADHD. It's like finding a new oasis in the desert, offering hope for those struggling with this condition. These promising new compounds represent a significant step forward in personalized medicine, allowing us to tailor treatment to meet the unique needs of each patient.

Date :
  1. Date Completed 2020-08-20
  2. Date Revised 2020-08-20
Further Info :

Pubmed ID

31167583

DOI: Digital Object Identifier

10.1080/14737175.2019.1628640

Related Literature

Article Analysis
・Effects of molindone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.